Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 202 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CC-4047 Clear all
Recruiting Phase 1 Interventional

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Myeloma Multiple
Interventions
Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Drug
Lead sponsor
K36 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

NCT07772024
View directory record Official record
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
InoPd, Investigator's choice of SAT
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

NCT02294357
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Encinitas, California • West Hills, California • West Hollywood, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

NCT00537511
View directory record Official record
Conditions
Carcinoma, Small Cell
Interventions
Pomalidomide, Cisplatin, Etoposide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Cleveland, Ohio • Hershey, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 4, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07222761
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

NCT01638936
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BT062 , intravenous administration
Drug
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 4, 2026, 4:37 AM EDT
Completed No phase listed Observational

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT04458831
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

NCT04895410
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lemzoparlimab, Dexamethasone, Carfilzomib, Pomalidomide, Daratumumab
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

NCT02548962
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ibrutinib, Pomalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01665794
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Carfilzomib, dexamethasone, Daratumumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional

Combination Study for High Risk Multiple Myeloma Patients

NCT03104270
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Encinitas, California • Fountain Valley, California • Monterey, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

NCT03030261
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Suspended Phase 2 Interventional

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

NCT03798314
View directory record Official record
Conditions
Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
Interventions
Nivolumab, Pomalidomide
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687
View directory record Official record
Conditions
Multiple Myeloma
Interventions
pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
10
States / cities
Basking Ridge, New Jersey • New Brunswick, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

NCT02807454
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT04835129
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 4:37 AM EDT